After FDA exit, Peter Marks pops up at Lilly скачать в хорошем качестве

After FDA exit, Peter Marks pops up at Lilly

In today’s headlines – 8 October: The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research. Johnson & Johnson has suffered a setback in its long-running legal defence against claims its talc products cause cancer. Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success? Sanofi has said clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings. CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE. Subscribe to @Pharmaphorum for daily news updates and check out www.pharmaphorum.com for more insights and analysis. #news #pharma #pharmanews #pharmainnovation #pharmaindustry #lifesciences #biotechnews #biopharma #drugdevelopment #drugdiscovery #fda #fdaregulations #cber #elililly #infectiousdisease #johnsonandjohnson #talc #boehringeringelheim #sanofi #novartis #cslbehring #nhs As an official Frontiers Health conference partner, we are pleased to offer pharmaphorum readers an exclusive 20% discount. Don’t miss this unique opportunity to engage with some of the brightest minds in modern healthcare to discuss the biggest trends, opportunities, and challenges facing today’s health innovators. Click below and use promo code: FH25PHP20 to register at a reduced price: https://www.frontiers.health/2025-reg...